COVID drug molnupiravir appears to be driving SARS-CoV-2 to

Molnupiravir, an antiviral drug used to treat patients with COVID-19, appears to be driving SARS-CoV-2 to mutate and evolve, with some of these new viruses being transmitted onwards, a new study has shown. It is not clear, however, whether these mutated viruses pose an increased risk to patients or are able to evade the vaccine.

Related Keywords

United Kingdom , United States , Japan , Cambridge , Cambridgeshire , South Africa , Theo Sanderson , Fondation Botnar , Christopher Ruis , Megan Craig , Francis Crick Institute , University Of Cambridge , Oxford Martin School , National Institute For Health , Wellcome , Research Council , Cancer Research United Kingdom , United Kingdom Cystic Fibrosis , International Nucleotide Sequence Database Collaboration , Global Initiative On Sharing All Influenza Data , Genomics United Kingdom Consortium , Department Of Medicine , Care Research , United Kingdom Consortium , Global Initiative , Sharing All Influenza Data , Whilec To T , Medical Research Council , National Institute , United Kingdom Cystic Fibrosis Trust , Oxford Martin , Covid 19 , Cars , Ars Cov 2 , Antiviral Drug , Drugs , Revolution , Enome , Medicine , Ucleotide , Research , Vaccine , Virus ,